DKK 411.6
(6.85%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 625.28 Million DKK | 137.84% |
2022 | 262.9 Million DKK | -12.98% |
2021 | 302.12 Million DKK | 54.8% |
2020 | 195.17 Million DKK | 14.75% |
2019 | 170.08 Million DKK | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 610.76 Million DKK | -2.32% |
2024 Q2 | 610.76 Million DKK | 0.0% |
2023 FY | 625.28 Million DKK | 137.84% |
2023 Q3 | 625.28 Million DKK | 0.3% |
2023 Q2 | 623.41 Million DKK | 0.0% |
2023 Q4 | 625.28 Million DKK | 0.0% |
2023 Q1 | 623.41 Million DKK | 137.13% |
2022 Q4 | 262.9 Million DKK | 0.0% |
2022 FY | 262.9 Million DKK | -12.98% |
2022 Q3 | 262.9 Million DKK | 0.0% |
2022 Q1 | - DKK | 0.0% |
2021 FY | 302.12 Million DKK | 54.8% |
2020 FY | 195.17 Million DKK | 14.75% |
2019 FY | 170.08 Million DKK | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
ALK-Abelló A/S | 6.72 Billion DKK | 90.704% |
Bavarian Nordic A/S | 14.35 Billion DKK | 95.644% |
Genmab A/S | 35.28 Billion DKK | 98.228% |
Novo Nordisk A/S | 314.48 Billion DKK | 99.801% |
Orphazyme A/S | 19.31 Million DKK | -3137.78% |
Pharma Equity Group A/S | 81.33 Million DKK | -668.771% |
Zealand Pharma A/S | 3.19 Billion DKK | 80.453% |